ANIX

Anixa Biosciences, Inc. | Healthcare

8.97704%

Analisi Pre-Earnings (Antonio AI)

2025-12-18
Sentiment
95.0/100
Salute

Caution

Verdict

The narrative is explosive with positive Phase 1 data and new patents fueling a massive momentum run. 🔥 But the financials are a complete black box; we're flying blind on cash burn, which is a huge risk. ⚠️

Catalysts
  • Extremely positive Phase 1 data for the breast cancer vaccine, which has the market euphoric.
  • Strong, confirmed price momentum following recent news, attracting technical traders.
  • Steady drumbeat of news including patents and WHO milestones, keeping the stock in the spotlight.
Rischi
  • The company is a pre-revenue biotech and the unknown cash burn rate could force a sudden, dilutive share offering at any moment, crushing the rally.
Approfondisci con Antonio
Valutazione
P/E (TTM)-11.660119679349668
Forward P/E-11.660119679349668
P/S0.0
Market Cap171809812
Finanze & Debito
CashNone
DebtNone
Debt/Equity0.012835191322687556
Current Ratio8.445788964181995
Redditività
ROE-0.5024321756271893
Profit Margin0.0
Operating Margin0.0
Rev. Growth-1.0
Ultime News (Context per AI)